Simona Skerjanec

Global Launch Leader, Anti-Platelet Solutions at The Medicines Co.

Simona Skerjanec

Simona Skerjanec

Global Launch Leader, Anti-Platelet Solutions at The Medicines Co.

Overview
RelSci Relationships

1834

Number of Boards

1

Relationships
RelSci Relationships are individuals Simona Skerjanec likely has professional access to. A relationship does not necessarily indicate a personal connection.

President at EcoHealth Alliance, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Rempex Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at The Medicines Co.

Relationship likelihood: Strong

Operating Partner at Main Street Resources LLC

Relationship likelihood: Strong

Former Senior Vice President, Human Resources at Ziff Brothers Investments LLC

Relationship likelihood: Strong

Chief Administrative Officer at Stream Line Circle LLC

Relationship likelihood: Strong

Chief Executive Officer at Innocrin Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Financial Officer & Treasurer at The Medicines Co.

Relationship likelihood: Strong

Executive Vice President, General Counsel & Secretary at The Medicines Co.

Relationship likelihood: Strong

Director at American Diabetes Association, Inc.

Relationship likelihood: Strong

Paths to Simona Skerjanec
Potential Connections via
Relationship Science
You
Simona Skerjanec
Global Launch Leader, Anti-Platelet Solutions at The Medicines Co.
Career History
Global Launch Leader, Anti-Platelet Solutions
2003 - Current

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Director of Life Cycle Planning
Prior

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Director of Life Cycle Planning
Prior

Johnson & Johnson Services, Inc., a subsidiary of Johnson & Johnson, is a company headquartered in New Brunswick, NJ. The firm provides home and health care services.

Boards & Committees
Member, Board of Directors
Prior - 2017
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Simona Skerjanec. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Simona Skerjanec's profile does not indicate a business or promotional relationship of any kind between RelSci and Simona Skerjanec.